Technology & IP
A portfolio built at the frontier of iPSC biology and autonomous manufacturing.
32+ patents across six technology domains — from hypoimmune cell engineering to AI-driven biomanufacturing systems.
Patent Portfolio
Six technology domains.
iPSC Reprogramming & Banking
Blood, LCL, and cord blood reprogramming methods. cGMP suspension culture systems. Cell banking and characterization protocols for clinical-grade iPSC lines.
Cell Differentiation & Manufacturing
Large-scale iEC manufacturing. iPSC-derived islet differentiation methods. Smooth muscle cell protocols. Islet co-culture systems for enhanced function.
Organ-on-Chip & Microphysiological Systems
NMJ-on-chip systems for neuromuscular disease. Spinal cord chip platforms. Intestinal microphysiological systems. Infection and pathogen modeling devices.
Bioengineered Tissues & Organoids
3D bioprinting of vascularized constructs. Prevascularized organoid systems. iEC-microgel platforms for transplantation. Scaffold-based tissue engineering.
Hypoimmune & Immune Evasion
HIDE-iPSC platform for universal donor design. Off-the-shelf cell therapy engineering. Immune evasion strategies for allogeneic cell products without immunosuppression.
Autonomous Biomanufacturing
Robotic systems for closed-loop iPSC manufacturing. AI-driven quality control platforms. Digital twin infrastructure for bioprocess modeling and regulatory support.
Licensing
Three collaboration tracks.
Exclusive License
Full field-of-use exclusive licensing for commercial development. Ideal for companies building proprietary cell therapy products.
Non-Exclusive License
Broad access to platform technologies for multiple commercial partners in non-competing fields.
Co-Development
Joint development agreements with IP sharing provisions. Best for early-stage technology requiring additional development investment.
Interested in licensing?